Figure 3
From: Sclerostin expression in trabecular bone is downregulated by osteoclasts
Expression of sclerostin, β-catenin, and ALP in the anti-RANKL antibody-treated C57BL/6 mice. (A) Immunohistochemical analysis of sclerostin in the trabecular area of the femur from C57BL/6 mice at 12 weeks of age injected with vehicle (left panels) or the anti-RANKL antibody (right panels). (B) Sclerostin-positive cells/bone area (N/mm2). (n = 6). (C) Measurement of sclerostin in bone marrow aspirates from C57BL/6 mice injected with vehicle or the anti-RANKL antibody using ELISA (n = 6). (D) Immunohistochemical analysis of β-catenin in the trabecular area of the femur from C57BL/6 mice injected with vehicle (left panels) or the anti-RANKL antibody (right panels). (E) β-catenin-positive cells/bone surface (N/mm). (n = 6). (F) Analysis of Axin2 mRNA expression in tibiae of C57BL/6 mice at 12 weeks of age injected with vehicle or the anti-RANKL antibody using real-time RT-PCR (n = 6). (G) Immunohistochemical analysis of ALP in the trabecular area of the femur from C57BL/6 mice injected with vehicle (left panel) or the anti-RANKL antibody (right panel). (H) ALP activity in serum from C57BL/6 mice injected with vehicle or the anti-RANKL antibody (n = 6). (I) Histological analysis of Villanueva Goldner staining in the trabecular area of the tibiae from C57BL/6 mice injected with vehicle (top left panel) or the anti-RANKL antibody (top right panel). The lower two panels show double labeling of calcein. (J) Bone histomorphometry analysis of mineral apposition rate (MAR) in the tibiae from C57BL/6 mice injected with vehicle (left panel) or the anti-RANKL antibody (right panel). (n = 6). (K) Bone histomorphometry analysis of bone formation rate (BFR) in the tibiae from C57BL/6 mice injected with vehicle (left panel) or the anti-RANKL antibody (right panel) (n = 6). *p < 0.05, **p < 0.01. Scale bar, 50 μm.
